Objectives: To detect prostate cancer in young black men and compare our results with those of western studies.
Patients And Methods: The authors conducted a prospective multicenter study from February 2008 to May 2009 on 220 men aged 40 to 49 years. All patients with an abnormal prostate suspicious of cancer and/or a PSA greater than 2.5 ng/ml had a prostate biopsy.
Results: The mean age of patients was 44.99 years. The mean PSA was 26.62 ng/ml and ranged from 0.3 to 5600 ng/ml, with a median PSA of 0.88 ng/ml. Eleven patients had a PSA greater than 2.5 ng/ml and three had abnormal prostates suspicious of cancer. Twelve patients had a prostate biopsy. Histologic studies of the specimens found one case of prostate adenocarcinoma (Gleason 4+4) and two cases of high grade prostate intraepithelial neoplasia (HGPIN), all within the 46 to 50 years age group.
Conclusion: Due to the absence of prostate cancer within the 40 to 45 years age group, we would not recommend the screening of prostate cancer within this age group. This is only a preliminary study, and should be completed with the search for familial forms of prostate cancer. Also, a regular follow-up of patients already presenting with PSA greater than 2.5 ng/ml or HGPIN should be considered.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.purol.2010.05.011 | DOI Listing |
JAMA Netw Open
January 2025
Department of Epidemiology and Biostatistics, University of California, San Francisco.
Importance: Incidence of distant stage prostate cancer is increasing in the United States. Research is needed to understand trends by social and geographic factors.
Objective: To examine trends in prostate cancer incidence and mortality rates in California by stage, age, race and ethnicity, and region.
Endocrine
January 2025
Department of Zoology, Institute of Science, Banaras Hindu University, Varanasi, Uttar Pradesh, India.
The word "cancer" evokes myriad emotions, ranging from fear and despair to hope and determination. Cancer is aptly defined as a complex and multifaceted group of diseases that has unapologetically led to the loss of countless lives and affected innumerable families across the globe. The battle with cancer is not only a physical battle, but also an emotional, as well as a psychological skirmish for patients and for their loved ones.
View Article and Find Full Text PDFInvest New Drugs
January 2025
School of Life Sciences, Jilin University, Changchun, China.
Due to the emergence of drug resistance, androgen receptor (AR)-targeted drugs still pose great challenges in the treatment of prostate cancer, and it is urgent to explore an innovative therapeutic strategy. MK-1775, a highly selective WEE1 inhibitor, is shown to have favorable therapeutic benefits in several solid tumor models. Recent evidence suggests that the combination of MK-1775 with DNA-damaging agents could lead to enhanced antitumor efficacy.
View Article and Find Full Text PDFJ Natl Cancer Inst
January 2025
Department of Urology, Vanderbilt University Medical Center, Nashville, TN, United States.
Front Oncol
January 2025
Department of Urology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.
The prediction of survival outcomes is a key factor in making decisions for prostate cancer (PCa) treatment. Advances in computer-based technologies have increased the role of machine learning (ML) methods in predicting cancer prognosis. Due to the various effective treatments available for each non-linear landscape of PCa, the integration of ML can help offer tailored treatment strategies and precision medicine approaches, thus improving survival in patients with PCa.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!